Expression Of CD44+/CD24-, RAD6 and DDB2 On Chemotherapy Response In Ovarian Cancer: A Prospective Flow Cytometry Study

Unedo Hence Markus Sihombing (mailto:unedoedo@yahoo.com)
Tarakan Hospital

Andrijono Andrijono
Universitas Indonesia - Cipto Mangunkusumo Hospital

Gatot Purwoto
Universitas Indonesia - Cipto Mangunkusumo Hospital

Supriadi Gandamihardja
Hasan Sadikin Hospital, Universitas Padjadjaran

Alida R. Harahap
Universitas Indonesia - Cipto Mangunkusumo Hospital

Primadiewi Rustamadji
Universitas Indonesia - Cipto Mangunkusumo Hospital

Aria Kekalih
Universitas Indonesia

Retno Widyawati
Universitas Indonesia

Dzicky Rifqi Fuady
Tarakan Hospital

Research Article

Keywords: Ovarian Cancer, CD44+/CD24-, RAD6, DDB2, chemoresistance

Posted Date: June 3rd, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1440070/v3

License: ☀️ 📧 This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Backgrounds:** Ovarian cancer is the 8th deadliest common cancer in women around the world. Almost all ovarian cancer patients would experience chemoresistance, recurrence, and poor prognosis after cytoreductive surgery and platinum-based chemotherapy. Chemoresistant cancer cells have characteristic expressions of cancer stem cell proteins (CSCs) CD44+/CD24−, RAD6, and DDB2. The increased expression of CD44+/CD24−, RAD6, and decreased DDB2 are believed to be associated with chemoresistance, recurrence, and poor prognosis of the disease. Thus, this study’s objective is to analyze the correlation between the expression of CD44+/CD24−, RAD6 and DDB2 with ovarian cancer chemoresistance.

**Materials and methods:** This study was conducted with a prospective cohort of 64 patients who is divided into two groups (32 patients in each group) at the Obstetrics-gynecology and pathology department of Cipto Mangunkusumo, Tarakan, Dharmais, and Fatmawati Hospital. All suspected ovarian cancer patients underwent cytoreductive debulking and histopathological examination. Chemotherapy was given for six series followed by six months of observation. After the observation, we determined the therapy’s response with the RECIST Criteria (Response Criteria in Solid Tumors) and then classified the results into chemoresistant or chemosensitive groups. Flow cytometry blood tests were then performed to examine the expression of CD44+/CD24−, RAD6 and DDB2.

**Results:** There was a significant relationship between increased levels of CD44+/CD24− and RAD6 (p <0.05) levels with the chemoresistance of ovarian cancer. The logistic regression test showed that the CD44+/CD24− was better marker.

**Conclusions:** These results indicate that CD44+/CD24− and RAD6 expressions are significantly associated with ovarian cancer chemoresistance, and CD44+/CD24− is the better marker to predict ovarian cancer chemoresistance.

**Introduction**

Ovarian cancer is the 8th deadliest common cancer in women worldwide. In 2018, there were 295,414 new cases with 184,799 deaths. In Indonesia, of 188,231 cancer diagnoses, 13,310 (7.1%) were ovarian cancer cases with an incidence of 9.7 per 100,000 cases (1). The standard treatment for ovarian cancer is cytoreductive surgery followed by platinum-based chemotherapy. However, almost all patients would experience disease recurrence. Recent studies have stated that standard therapy had a chemosensitivity and chemoresistance rate of 77.4% and 18.1%, respectively. Furthermore, ovarian cancer patients were found to have a 12-month progression-free survival (PFS) with overall survival (OS) period of about 30 months (2, 3). The low survival rate of ovarian cancer patients is due to chemotherapy resistance caused by cancer stem cell (CSCs) proteins.

CSCs are believed to have an association with the initiation of tumors, tumor growth, metastasis, recurrence, and the presence of resistance. Meng *et al.* stated that ovarian stem cell cancer with
CD44⁺/CD24⁻ was 71-93% resistant to all chemotherapy agents, has a recurrence rate of 83% (p = 0.003), and a median PFS of 6 months (4). Hu et al. also found that CD44⁺ was positively expressed in the chemotherapy-resistant ovarian cancer patients with a statistically significant value of 91.17% with p < 0.05 (5).

Attention to CSCs mechanism has focused on the DNA damage response (DDR) in the tumorigenic process. Increased DDR can prevent the formation of CSCs and chemoresistant cells. The DDR pathway consists of post replication repair (PRR), nucleotide excision repair (NER), etc. The process of NER occurs through several DNA binding proteins, such as DNA damage binding protein 2 (DDB2 or XPE) while in the PRR process and an expression of E2 ubiquitin-conjugating enzymes (UBE2) protein, such as RAD6 (6).

RAD6 is a UBE2 protein required for DNA regulation and is associated with mitotic abnormalities and cell transformation. Increased expression of RAD6 enhances stemness function, chemoresistance, progression, and metastasis. The RAD6 on DNA is associated with chemoresistance and poor clinical prognosis in ovarian cancer. Somasagara et al. reported that RAD6 expression <5 and >5 was associated with 37.5% and 70% recurrence, respectively (7). DDB2 is also an amino acid that plays a role in the nucleotide excision DNA repair process. Low expression of DDB2 correlates with increased chemotherapy resistance and leads to a poor prognosis (6). Han C et al. found that DDB2 mRNA expression levels >0.5 had a better prognosis than values <0.5 (8). This decrease in protein expression is associated with a reduction in life expectancy (9).

Most cancer cells are sensitive to chemotherapy, but some CSCs could not be detected and would develop into disease recurrence. CSC resistance will make the cells continue to move into the mitotic and interphase (G1, S, G2), while the G0/rest phase is inactive and continuously replicating (10). This study aims to find correlations between CD44⁺/CD24⁻·RAD6, and DDB2 with chemotherapy response in ovarian cancer and the ability of the three markers to predict ovarian cancer chemotherapy response. We hypothesize that the three markers have a relationship with ovarian cancer and can be predictors of it. The results of this study can be used as proof for these markers to be used as predictors and have the potential to be developed as targets for gene therapy.

**Materials And Methods**

**Study Design**

This study used a prospective cohort at the obstetrics-gynecology and anatomical pathology department of Cipto Mangunkusumo Hospital, Tarakan Hospital, Dharmais Hospital, and Fatmawati Hospital from February 2018 until February 2022. The objective was to find correlations between CD44⁺/CD24⁻·RAD6, and DDB2 with chemotherapy response in ovarian cancer and investigate its predictive ability.

**Participants**
The research subjects were patients with ovarian carcinoma inclusion, stage II-IV epithelial ovarian cancer patients, and were willing to participate in the study. The exclusion criteria were pregnant patients and patients diagnosed with other types of cancer. The number of samples in this study was 64 patients who is divided into two groups (32 patients in each group) and the consecutive sampling method was used to avoid selection bias. Every patient suspected of ovarian cancer underwent cytoreductive debulking and histopathological examination. If the pathology result was malignant, chemotherapy was administered for six series followed by six months of observation. The patients who had signs of chemoresistance before 6 months of observation were completed (refractory chemoresistance) would be included in the sample.

**Data Collection**

After the observation, we determined the therapy’s response with the RECIST Criteria (Response Criteria in Solid Tumors) and then classified them into chemoresistant or chemosensitive groups. The patients were chemosensitive if there is no residual tumor lesion or pathological lymph node (complete response), and if there is a decrease of thirty percent (30%) in diameter of the longest lesion (partial response). Patients were chemoresistant if there was a twenty percent (20%) increase in the diameter of the smallest lesion and an increase of at least 5 mm in the old lesion, and then if there was a new lesion (progressive disease). Patients were also assigned chemoresistant if there was no sufficient shrinkage to meet the partial response category or was no sufficient enlargement for the disease group. We classified the therapy response by clinical examinations and CT scan or Doppler ultrasound depending on the availability of the hospital and the type of patients’ insurance. The evaluation by clinical examination, ultrasound, and CT scan were carried out before chemotherapy, after chemotherapy, and after 6 months of observation.

Flow cytometry blood tests were then performed to examine the patients’ expression of RAD6 and DDB2 and CSC (CD44+/CD24−). Blood was taken for a flow cytometry test after 6 months of post-chemotherapy observation was completed. if there are patients who experience chemoresistance before the observation period is over, blood will be taken directly at that time for flow cytometry examination before the 6-month observation period is completed. In addition, demographic data, cancer stage, operation type, chemotherapy response, tumor cell differentiation (cancer stage), cancer histopathology, cancer size, cancer residue, ascites, lymph node metastasis, and serum Ca-125 levels were also taken. The staging of the disease was conducted using the FIGO criteria.

**Flow cytometry**

Blood was taken from peripheral blood at five cc and then centrifugated. The supernatant was discarded, and 50 µL was left, after which the cell mixture was resuspended. The markers identified expression CD44+/CD24−, RAD6, and DDB2. The samples were reacted with fluorescent-labeled antibody against CD44+/CD24− (monoclonal anti-human), CD44+ was labeled as PerCP, CD24− was labeled as APC, RAD6 was labeled as PE, and DDB2 was labeled FITC. The four reagents were then removed for leukocytes with
CD45 labeled pacific blue. The samples in the Falcon tube were then added with 2.5 µL of CD44 marker, 2.5 µL of CD24 marker, and 2.5 µL of RAD6 and DDB2. Next, they were incubated for 15 minutes in the dark at room temperature. After incubation, the cells were lysed by using 300 µL of lysing solution, then set again for 15 minutes in a dark room and at room temperature. Next, 1 mL of FACS flow solution was added and centrifuged at 500 g for 5 minutes. The supernatant formed was then discarded, added with 500 µL perm wash buffer and centrifuged at 500 g for 5 minutes; the supernatant created was discarded. To be more optimal, 1mL perm wash buffer was added again and centrifuged at 500 g for 5 minutes. The last step was to add 200 µL of 1% paraformaldehyde in phosphate-buffered saline (PBS). After that, the analysis was conducted by using a flow cytometer using four fluorochrome colors.

Next, cell identification was conducted by using an automated flow cytometer (BD Facs Calibur). CSCs were then identified through the positive expression of CD44+/CD24- markers and RAD6 and DDB2 were conducted through a positive expression of RAD6 and DDB2 markers with four different colors. Protein percentage is the percentage of expression of protein markers CSCs (CD44+/CD24-), RAD6, and DDB2 in the blood.

**Statistical Analysis**

We analyzed the univariate, bivariate, and multivariate analyses. Each categorical variable was tested with the chi-square or Fisher test while the numerical variables were tested with an unpaired t-test or Mann-Whitney according to the normality test result. Multivariate analysis was also performed using logistic regression.

**Ethics approval**

Research ethics approval was obtained from the Health Research Ethics Committee of the Universitas Indonesia, Cipto Mangunkusumo Hospital. All patients have given their informed consent to participate.

**Results**

**Basic Participants’ Characteristics**

The total sample in this study was 32 samples in each group with a total of two groups. All samples had undergone chemotherapy with 32 (50%) chemoresistance and 32 (50%) chemosensitive without any missing data or lost follow-up patients after 6 months of observation. Some patients have signs of chemoresistance before 6 months of observation and they were included in the sample. The distribution of profiles and clinical characteristics of ovarian cancer patients can be seen in Table 1. All the patients with stage II-IV epithelial ovarian cancer patients were included in the samples.

**Flow cytometry of Ovarian cancer**

The example of flow cytometry data is described in Figures 2 and 3. The proportion of CD44+/CD24-, RAD6, and DDB2 values were calculated based on the percentage of the total cells. CD44+/CD24- was
calculated based on the proportion of purple CD44⁺/CD24⁻ cells. RAD6 (UBE2) was calculated based on the ratio of orange, purple, and single UBE2 cells; DDB2 was calculated based on the proportion of green, orange, and white colors.

**Bivariate Analysis**

Table 2 shows that CD44⁺/CD24⁻, RAD6, Ca-125, type of surgery, lymph node metastasis, and tumor residue have significant difference results (p < 0.05) with each odds ratio (OR) and relative risk (RR) value. We found that all markers have significant correlations with ovarian cancer chemoresistance (p < 0.05) while CD44⁺/CD24⁻ has the highest current odds ratio (OR) value (10.7) and relative risk (RR) value (3.19) in the future outcomes.

**ROC (Receiver Operating Characteristic Curve) and AUC (Area Under the Curve)**

The ROC curve in Figure 1 and Table 3 data showed that the CD44⁺/CD24⁻ protein has the better ROC curve and AUC value. The AUC value of the CD44⁺/CD24⁻ is 0.783 (moderate accuracy), with significant value (p < 0.05, the sensitivity is 78%, and its specificity is 75%). RAD6 protein had an AUC of 0.586 (very weak accuracy), not significant (p > 0.05), with a sensitivity of 84% and specificity of 46%. DDB2 had an AUC value of 0.578 (very weak accuracy), not significant (p > 0.05), sensitivity 59%, and specificity of 53%.

**Multivariate Analysis**

The multivariate results of table 4 showed that CD44⁺/CD24⁻ has better value with a significant p-value (p < 0.05) with Exp (B) value is 12.713. It means that ovarian cancer patients with high expression of CD44⁺/CD24⁻ have a higher 12.713 times risk for chemoresistance than the patients with low CD44⁺/CD24⁻.

**Discussion**

This is the first study about the expression CD44⁺/CD24⁻, RAD6, and DDB2 in ovarian cancer patients’ blood circulation directly by flow cytometry methods. Previous studies only study the expression of these proteins in the cultured cell lines. This study showed that there was an overexpression of CD44⁺/CD24⁻ and RAD6 in the chemoresistance ovarian cancer patients’ blood circulation. We found that there was no significant difference in DDB2 expression in the chemoresistance ovarian cancer patients’ blood circulation.

CD44⁺ (cluster of differentiation 44) and CD24⁻ expression are associated with increased ovarian cancer oncogenesis and progression (4, 12). CD44⁺ overexpression has also been found in the pancreatic cancer (13), breast cancer (14), gastric cancer (15), urothelial bladder cancer (16), and colorectal cancer (17). It is associated with metastasizing, recurrence, chemoresistance, and poor survival rates in
the ovarian cancer (18). CD24- is a cell surface adhesion molecule that is frequently detected in invasive ovarian carcinoma. High CD24- expression in invasive ovarian cancer predicts shorter overall survival than low CD24- markers (19).

CD44+CD24- is a good predictor of ovarian cancer chemoresistance. We found that higher CD44+/CD24- has a significant result (p < 0.05) with moderate accuracy (AUC 0.7-0.8) with a sensitivity of 78% and specificity of 75%. Meng et al., (2012) also found that ovarian cancer cells with high CD44+/CD24- expression have stem cell characteristics: higher aggressive, invasive, progressive, and multiplicative properties in each tumor histology type. This ovarian cancer cell also has higher chemoresistance properties, recurrence rate, and aggravating prognosis (4).

Li et al., (2017) found that high CD44+/CD24- protein levels indicated breast tumor malignancy with higher rates of cell proliferation, tumorigenesis, and metastasis. It has also been found that breast cancer with CSC has resistance to chemotherapy and radiotherapy (20). Furthermore, Yan et al., (2013) found that cells with high CD44+/CD24- expression showed higher migration and invasion properties and were the cause of chemoresistance (21).

Moreover, a past study has found that there was higher CD44+ expression in paclitaxel-resistant cell lines than paclitaxel-sensitive cell lines in a mouse model that used ovarian cancer xenografts while patients with ovarian cancer showed that CD24- cells were more resistant to cisplatin and increased tumorigenesis ability (22). A meta-analysis study showed that the CD44+ protein was associated with poorer cancer-specific survival rates in patients undergoing chemoradiotherapy (23). Zhang et al., (2019) also found that high expression of markers CD105, CD44+, and CD106 are related to chemoresistance, as well as poorly differentiated and advanced-stage ovarian cancer (18).

RAD6 has a significant role in activating several DNA repair pathways and is substantial in chemoresistance in the ovarian cancer (24). RAD6 overexpression is associated with mitotic abnormalities and tumor progression (25). We found that there was a significant increase in RAD6 levels (p < 0.05) in chemoresistance patients. However, the ROC and AUC results were not significant (p > 0.05), and the accuracy was very weak (AUC 0.5-0.6), with a sensitivity value of 84% and specificity of 46%.

Clark et al., (2018) investigated the role of RAD6 in chemoresistant ovarian cancer by inhibiting RAD6A and RAD6B in several ovarian cancer cases. These cells showed the decreased expression of CSC markers, activation of DDR protein, and concomitant sensitivity to carboplatin responses, thereby suggesting that RAD6 expression increases after chemotherapy and causes chemoresistance in cancer cells through stimulating CSC protein expression and increasing DNA repair activity (25). Somasagara et al., (2016) found an association between chemoresistance and increased RAD6 in ovarian cancer cells through RAD6-mediated ubiquitin signaling, which led to increased DDR and CSC protein expression. In addition, a higher RAD6 (≥5.1) was also associated with a disease recurrence rate of 70% (11). Another study also concluded that RAD6 is related to the severity of ovarian cancer, breast cancer, and melanoma.
Additionally, RAD6 levels were significantly increased in severe ovarian cancer with platinum chemoresistance (26).

RAD6 overexpression can increase stem cell characteristics, making them more aggressive, metastasize, and relapse. The epigenetic influence of RAD6 causes the ubiquitination of some histone variants which then regulate genes related to DNA repair, cell resistance, and chemoresistance (26). RAD6 is also closely related to RAD18, a protein E3 ubiquitin ligase that regulates the DNA repair pathway in Fanconi anemia and the BRCA gene in breast cancer (11). RAD6 was also involved in breast cancer chemoresistance in which researchers inhibited RAD6 with a small molecule inhibitor and found an increased sensitivity to cisplatin (27). In bladder cancer, it was also found that overexpression of enzymes from the UBE2 group, one of which was RAD6, could affect the growth of bladder cancer cells. An experiment was conducted by stopping the expression of UBE2 which caused the cells to stop growing in the G2/M phase and increase the apoptosis of these cancer cells (28).

DDB2 is a protein localized in the cell nucleus that contributes to gene transcription, cell cycle progression, and protein degradation (29). The decrease in DDB2 also affects ovarian cancer's aggression, metastasis, and severity (7). This study found that DDB2 protein expression was found significantly lower in chemotherapy-resistant patients (p < 0.05). The ROC and AUC analysis results are p >0.05 with weak accuracy (AUC 0.6-0.7) as well as a sensitivity value of 37.5% and specificity of 37.5%.

DDB2 levels are high in the chemosensitive cancer patient group because DDB2 participates in the tumor suppression process in at least three ways: promoting the nucleotide excision repair (NER) process, supporting apoptosis, and inducing cell aging after DNA damage has occurred (30). Thus, the loss of DDB2 function in normal cells can lead to susceptibility to tumor growth. DDB2 gene mutation causes loss of function and gives rise to the phenotypic characteristics of Xeroderma Pigmentosum group E, which is characterized by malignant skin tumors. Mice with low DDB2 levels were found to not only be hypersensitive to UV-related carcinogenesis processes but also have a high incidence of broad-spectrum spontaneous malignant tumors from internal organs. Thus, DDB2 acts as a mediator in suppressing the p53 and BRCA1 pathways, thereby being a tumor cell suppressor. It protects against cancer by regulating the cell cycle and increasing the occurrence of apoptosis instead of being directly involved in the repair of DNA damage (31).

Most ovarian cancer cells have a low DDB2 expression (32). Barakat et al. investigated the expression of DDB2 in several cisplatin-resistant ovarian cancer cell lines, and the results obtained were lower DDB2 expression than in cisplatin-sensitive cells (33). The study also further explained that low DDB2 expression is associated with chemoresistance and poor patient prognosis (8). DDB2 can reduce excess CSC protein (CD44+/CD24−) in large ovarian cancer. Overexpression of DDB2 in human ovarian cancer cells decreased the ability of these tumor cells to replicate (8). Han et al., (2014) also stated that low DDB2 protein expression was associated with poor prognosis in ovarian cancer patients. Studies have also found that DDB2 deficiency causes ovarian tumors to relapse due to the expansion of the CSCs population (34).
Furthermore, according to Yang et al. (2018), DDB2 protein expression was associated with the onset, progression, and prognosis of colorectal cancer. Increased DDB2 expression was significantly associated with a better colorectal cancer prognosis (32). DDB2 was found to be able to inhibit colon cancer metastasizing through the mechanism of decreasing gene expression, which is an activator of Epithelial-to-Mesenchymal Transition (EMT) in colon cancer, and NF-κB was found in breast cancer (8). Decreased DDB2 also affects EMT activation by triggering squamous cell carcinomas in the head and neck region (9). Moreover, a study on non-small cell lung cancer (NSCLC) found that DDB2 can facilitate the process of breaking cancer cell growth. Conversely, if DDB2 decreases, the G2 cycle will continue and tumor growth and therapy resistance will occur (35).

Ovarian cancer chemoresistance and recurrence are possibly caused by the presence of residual cancer cells that have cancer stem cells (CSCs)(36). The known CSC pathways include Hedgehog, JAK/STAT, Nanog, Notch, PI3K/Akt, and Wnt/β-catenin that create stemness characteristics, such as self-renewal and differentiation ability into various types of cancer cells. In addition, there may be other unknown mechanisms in the CSCs (37).

The overexpression of RAD6 after chemotherapy was caused by DNA damage. RAD6 can cooperate with RAD18 to activate DDR mechanisms through several pathways such as the Fanconi Anemia (FA), Homologous Recombination (HR), and the Translesion Synthesis (TLS) pathway (7, 38). The interaction of RAD6 with RNF20/40 will cause histone monoubiquitylation and an increase of ALDHA1 and SOX-2 which causes epigenetic changes and gene transcription changes in chromatin structure. RAD6 can increase the activity of B-catenin by an unknown mechanism. The increased expression of some of the stemness factors mentioned above encourages chemotherapy resistance (38).

Multivariate analysis with logistic regression found that among the three markers, CD44+/CD24- is better marker to be used as a predictor of ovarian cancer chemoresistance in flow cytometry study. There were no flow cytometry previous studies about RAD6 and DDB2 with ovarian cancer chemoresistance before our research. This was the first research that used flow cytometry methods to analyze correlations between CD44+/CD24-, RAD6, and DDB2 directly in the ovarian cancer patients’ blood circulation. However, some shortcomings made us unable to prove that DDB2 low expression is correlated with ovarian cancer chemoresistance. Therefore, it cannot yet be used as a good predictor of ovarian cancer chemoresistance and require further research. We suggest that further research has a larger number of samples. We believe that in the future, expression of post-chemotherapy CD44+/CD24-, RAD6, and DDB2 in ovarian cancer patients’ blood circulation could be used to predict chemoresistance.

**Conclusion**

We conclude that there is a significant relationship between increased levels of CD44+/CD24- and RAD6 (p <0.05) with chemoresistance in ovarian cancer. The logistic regression results also indicate that CD44+/CD24- is better marker to be used as a predictor of ovarian cancer chemoresistance.
Declarations

**Ethics approval:** Ethical approval was granted by the Health Research Ethics Committee of the Universitas Indonesia, Cipto Mangunkusumo Hospital No. KET-230/UN2.F1/ETIK/PPM.00.02/2021, March 15th, 2021.

**Consent to participate:** Informed consent was obtained from all participants included in the study.

**Consent for publications:** Not applicable. We have no individual person's data in the manuscript. All authors have consented to publication.

**Availability of data and materials:** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interest:** All authors report there are no competing interests to declare

- **Unedo Hence Markus Sihombing:** no competing interests to declare.
- **Andrijono:** no competing interests to declare.
- **Gatot Purwoto:** no competing interests to declare.
- **Supriadi Gandamihardja:** no competing interests to declare.
- **Alida R. Harahap:** no competing interests to declare.
- **Primadiadewi Rustamadji:** no competing interests to declare.
- **Aria Kekalih:** no competing interests to declare.
- **Retno Widyawati:** no competing interests to declare.
- **Dzicky Rifqi Fuady:** no competing interests to declare.

**Funding:** The funding of this research was borne from all the authors. We had no support in the form of grants, equipment, drugs, etc.

**Authors contributions:** The authors contributions are equal.

- **Unedo Hence Markus Sihombing:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing.
- **Andrijono:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing.
- **Gatot Purwoto:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing.
• **Supriadi Gandamihardja:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing.

• **Alida R. Harahap:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing.

• **Primariadewi Rustamadji:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing.

• **Aria Kekalih:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing.

• **Retno Widyawati:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing.

• **Dzicky Rifqi Fuady:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing.

**Acknowledgements:** We would thank Cipto Mangunkusumo, Tarakan Hospital, Dharmais hospital, and Fatmawati Hospital for their support in this research. We would also like to acknowledge Christine Pamphila, M.D., Rasendah, M.D., Kristabella Gianina, M.D., for their contribution regarding the data analysis and collection conducted in this research.

**Tables**

Table 1. Essential Clinical Characteristics of Ovarian Cancer Patient
| Variable                        | Number (%) |
|--------------------------------|------------|
| Therapy response               | 32 (50)    |
| Chemoresistant                 | 32 (50)    |
| Chemosensitive                 |            |
| Age (years old)                |            |
| <40                            | 4 (6.3)    |
| 40-50                          | 19 (29.7)  |
| >50                            | 41 (64.1)  |
| Ca-125                         | 30 (46.9)  |
| £35                            | 34 (53.1)  |
| >35                            |            |
| Ovarian cancer stage           |            |
| Early stage: II                | 5 (7.8)    |
| Advance stage: III - IV        | 59 (92.2)  |
| Operation type:                |            |
| Optimal Debulking              | 56 (87.5)  |
| Suboptimal Debulking           | 8 (12.5)   |
| Differentiation/cancer grade   |            |
| Good                           | 13 (20.3)  |
| Intermediate                   | 16 (25.0)  |
| Poor                           | 35 (53.1)  |
| Tumor histology type           |            |
| Serous                         | 24 (37.5)  |
| High-grade serous              | 14 (21.9)  |
| Mucinous                       | 3 (4.7)    |
| Endometrioid                   | 12 (18.8)  |
| Clear cell                     | 10 (15.6)  |
| Others                         | 1 (1.6)    |
| Lymph nodes metastasis         |            |
| Positive                       | 32 (50)    |
| Negative                       |            |
| Ascites                        |            |
| Positive                       | 36 (56.3)  |
| Negative                       | 28 (43.7)  |
| Tumor size                     |            |
| 5 cm                           | 17 (26.6)  |
| 5-10 cm                        | 15 (23.4)  |
| >10 cm                         | 32 (50)    |
| Tumor residue                  |            |
| < 1 cm                         | 56 (87.5)  |
| > 1 cm                         | 8 (12.5)   |

Table 2 Bivariate Analysis of The Variables in Ovarian Cancer Patients.
| Variable | Therapy Response | P value | OR (CI 95%) | RR (CI 95%) |
|----------|------------------|---------|-------------|-------------|
|          | Chemoresistant (%) | Chemosensitive (%) |         |             |             |
| CD44+/CD24- expression | 25 (78.1) | 8 (25) | 0.001* | 10.7 | 3.19 |
|          | 7 (21.9) | 24 (75) |             | (3.3-34) | (1.69-6.0) |
| - High (≥32.692) | 15 (46.9) | 5 (15.6) | 0.007* | 4.76 | 2.45 |
| - Low (<32.692) | 17 (53.1) | 27 (84.4) |             | (1.4-15) | (1.1-5.4) |
| RAD6 expression | 15 (46.9) | 5 (15.6) | 0.007* | 4.76 | 2.45 |
|          | 17 (53.1) | 27 (84.4) |             | (1.4-15) | (1.1-5.4) |
| DDB2 Expression | 18 (56.3) | 15 (46.9) | 0.453 | 1.457 | 1.21 |
|          | 14 (43.7) | 17 (53.1) |             | (0.5-3.9) | (0.7-1.9) |
| Ca-125 Level | 2 (6.25) | 28 (87.5) | 0.000* | 105 | 7.93 |
|          | 30 (93.75) | 4 (12.5) |             | (17-618) | (3.14-20.0) |
| - £35 | 2 (6.25) | 28 (87.5) | 0.000* | 105 | 7.93 |
|          | 30 (93.75) | 4 (12.5) |             | (17-618) | (3.14-20.0) |
| - >35 | 1 (3.13) | 4 (12.5) | 0.162 | 4.42 | 1.68 |
|          | 31 (96.87) | 28 (87.5) |             | (0.47-42) | (1.7-4.4) |
| Ovarian cancer stage | 1 (3.13) | 4 (12.5) | 0.162 | 4.42 | 1.68 |
| - Early stage: II | 31 (96.87) | 28 (87.5) |             | (0.47-42) | (1.7-4.4) |
| - Advance stage: III - IV | 25 (84.4) | 31 (96.87) | 0.023* | 8.68 | 4.43 |
| Surgery type | 7 (15.6) | 1 (3.13) |             | (1.0-75.3) | (0.69-28.12) |
| - Optimal Debulking | 25 (84.4) | 31 (96.87) | 0.023* | 8.68 | 4.43 |
| - Suboptimal Debulking | 7 (15.6) | 1 (3.13) |             | (1.0-75.3) | (0.69-28.12) |
| Differentiation/cancer grade | 6 (18.75) | 7 (21.88) | 0.760 | 1.21 | 1.09 |
|          | 26 (81.25) | 25 (78.12) |             | (0.36-4.11) | (0.62-1.96) |
| - Good | 21 (65.63) | 11 (34.37) | 0.012* | 3.65 | 1.91 |
| - Intermediate - Poor | 11 (34.37) | 21 (65.63) |             | (1.29-10.2) | (1.1-3.2) |
| Lymph nodes metastasis | 18 (56.25) | 14 (43.75) | 1.000 | 1 | 1 |
|          | 14 (43.75) | 18 (56.25) |             | (0.37-2.68) | (0.61-1.64) |
| Ascites | 6 (18.8) | 8 (25) | 0.545 | 1.44 | 1.19 |
|          | 26 (81.2) | 24 (75) |             | (0.44-4.7) | (0.69-2.04) |
| Tumor size | 6 (18.8) | 8 (25) | 0.545 | 1.44 | 1.19 |
|          | 26 (81.2) | 24 (75) |             | (0.44-4.7) | (0.69-2.04) |
| - £5 cm | 25 (84.4) | 31 (96.87) | 0.023* | 8.68 | 4.43 |
|          | 7 (15.6) | 1 (3.13) |             | (1.0-75.3) | (0.69-28.12) |
| - > 5 cm | 25 (84.4) | 31 (96.87) | 0.023* | 8.68 | 4.43 |
| Tumor residue | 7 (15.6) | 1 (3.13) |             | (1.0-75.3) | (0.69-28.12) |

Note: *: p <0.05, Significant results.

**Table 3. AUC analysis of CD44+/CD24-, RAD6, and DDB2 variables**
### Table 4 Logistic regression of CD44+/CD24-, RAD6, and DDB2 variables

| No | Variables       | Beta value (B) | Standard deviation | Wald  | Exp (B) | p value | 95% CI         |
|----|-----------------|----------------|--------------------|-------|---------|---------|----------------|
| 1  | CD44+/CD24-     | 2.125          | 0.613              | 11.999| 8.369   | 0.001*  | 2.515-27.846  |
| 2  | RAD6            | 0.914          | 0.684              | 1.783 | 2.493   | 0.182   | 9.533         |
|    | Constant        | -1.239 ()      | 0.462              | 7.192 | 0.290   | 0.007   |                |

Note: *: p <0.05, significant

### References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

2. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-53.

3. du Bois A, Baert T, Vergote I. Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. J Clin Oncol. 2019;37(27):2398-405.

4. Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E, et al. CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis. 2012;29(8):939-48.

5. Zhenhua Hu JG, Danye Zhang, Qing Liu, Limei Yan, Lili Gao, Juanjuan Liu, Dawo Liu, Shulan Zhang, Bei Lin. High Expression of Lewis y Antigen and CD44 Is Correlated with Resistance to Chemotherapy in Epithelial Ovarian Cancers. PloS one. 2013;8(2).

6. Abad E, Graifer D, Lyakhovich A. DNA damage response and resistance of cancer stem cells. Cancer Lett. 2020;474:106-17.
7. Somasagara RR, Tripathi K, Spencer SM, Clark DW, Barnett R, Bachaboina L, et al. Rad6 upregulation promotes stem cell-like characteristics and platinum resistance in ovarian cancer. Biochem Biophys Res Commun. 2016;469(3):449-55.

8. Han C, Zhao R, Liu X, Srivastava A, Gong L, Mao H, et al. DDB2 suppresses tumorigenicity by limiting the cancer stem cell population in ovarian cancer. Molecular Cancer Research. 2014;12(5):784-94.

9. Bommi PV, Ravindran S, Raychaudhuri P, Bagchi S. DDB2 regulates Epithelial-to-Mesenchymal Transition (EMT) in Oral/Head and Neck Squamous Cell Carcinoma. Oncotarget. 2018;9(78):34708-18.

10. Alberts B JA, lewis J, Morgan D, Raff M, Robert K, Walter P. Molecular Biology of the Cell (6 edition) 6 th ed: Garland Science; 2008.

11. Somasagara RR, Spencer SM, Tripathi K, Clark DW, Mani C, Madeira da Silva L, et al. RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance. Oncogene. 2017;36(48):6680-90.

12. Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem cells translational medicine. 2015;4(9):1033-43.

13. Li L, Hao X, Qin J, Tang W, He F, Smith A, et al. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterology. 2014;146(4):1108-18. e12.

14. Hu J, Li G, Zhang P, Zhuang X, Hu G. A CD44v+ subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity. Cell death & disease. 2017;8(3):e2679-e.

15. Wang W, Dong L-P, Zhang N, Zhao C-H. Role of cancer stem cell marker CD44 in gastric cancer: a meta-analysis. International journal of clinical and experimental medicine. 2014;7(12):5059.

16. Hofner T, Macher-Goeppinger S, Klein C, Schillert A, Eisen C, Wagner S, et al., editors. Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy. Urologic Oncology: Seminars and Original Investigations; 2014: Elsevier.

17. Wang Z, Tang Y, Xie L, Huang A, Xue C, Gu Z, et al. The prognostic and clinical value of CD44 in colorectal cancer: a meta-analysis. Frontiers in oncology. 2019;9:309.

18. Zhang J, Yuan B, Zhang H, Li H. Human epithelial ovarian cancer cells expressing CD105, CD44 and CD106 surface markers exhibit increased invasive capacity and drug resistance. Oncology letters. 2019;17(6):5351-60.

19. Li S-S, Ma J, Wong AS. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism. Journal of gynecologic oncology. 2018;29(2).
20. Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Scientific reports. 2017;7(1):1-15.

21. Yan W, Chen Y, Yao Y, Zhang H, Wang T. Increased invasion and tumorigenicity capacity of CD44+/CD24-breast cancer MCF7 cells in vitro and in nude mice. Cancer cell international. 2013;13(1):1-7.

22. Gao M, Choi Y, Kang S, Youn J, Cho N. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010;29(18):2672-80.

23. Han S, Huang T, Li W, Wang X, Wu X, Liu S, et al. Prognostic value of CD44 and its isoforms in advanced cancer: a systematic meta-analysis with trial sequential analysis. Frontiers in oncology. 2019;9:39.

24. Spencer SM, Somasagara RR, Tripathi K, Bachaboina L, Scalici JM, Rocconi RP, et al. Rad6 inhibition sensitizes ovarian cancer cells to platinum drugs by attenuating activation of multiple DNA repair networks. Gynecologic Oncology. 2016;141:67-8.

25. Clark DW, Mani C, Palle K. RAD6 promotes chemoresistance in ovarian cancer. Molecular & Cellular Oncology. 2018;5(1):e1392403.

26. Omy TR, Jonnalagadda S, Reedy M, Palle K. RAD6-mediated epigenetic reprogramming contributes to therapy-induced chemo-resistance in ovarian cancer. AACR; 2021.

27. Haynes B, Gajan A, Nangia-Makker P, Shekhar MP. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2020;1866(1):165561.

28. Gong YQ, Peng D, Ning XH, Yang XY, Li XS, Zhou LQ, et al. UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells. Oncology letters. 2016;12(6):4485-92.

29. Gilson P, Drouot G, Witz A, Merlin J-L, Becuwe P, Harlé A. Emerging roles of DDB2 in cancer. International Journal of Molecular Sciences. 2019;20(20):5168.

30. Stoyanova T, Roy N, Battacharjee S, Kopanja D, Valli T, Bagchi S, et al. p21 cooperates with DDB2 protein in suppression of ultraviolet ray-induced skin malignancies. Journal of Biological Chemistry. 2012;287(5):3019-28.

31. Kattan Z, Marchal S, Brunner E, Ramacci C, Leroux A, Merlin JL, et al. Damaged DNA binding protein 2 plays a role in breast cancer cell growth. PloS one. 2008;3(4):e2002.
32. Yang H, Liu J, Jing J, Wang Z, Li Y, Gou K, et al. Expression of DDB2 Protein in the Initiation, Progression, and Prognosis of Colorectal Cancer. Digestive Diseases and Sciences. 2018;63(11):2959-68.

33. Barakat BM, Wang QE, Han C, Milum K, Yin DT, Zhao Q, et al. Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis. International journal of cancer. 2010;127(4):977-88.

34. Han C, Zhao R, Liu X, Srivastava AK, Gong L, Mao H, et al. Loss of DDB2 enhances the tumorigenicity of ovarian cancer cells through expanding cancer stem-like cell population. AACR; 2014.

35. Zou N, Xie G, Cui T, Srivastava AK, Qu M, Yang L, et al. DDB2 increases radioresistance of NSCLC cells by enhancing DNA damage responses. Tumor Biology. 2016;37(10):14183-91.

36. Suster NK, Virant-Klun I. Presence and role of stem cells in ovarian cancer. World journal of stem cells. 2019;11(7):383.

37. Pieterse Z, Amaya-Padilla MA, Singomat T, Binju M, Madjid BD, Yu Y, et al. Ovarian cancer stem cells and their role in drug resistance. Int J Biochem Cell Biol. 2019;106:117-26.

38. Clark DW, Mani C, Palle K. RAD6 promotes chemoresistance in ovarian cancer. Mol Cell Oncol. 2018;5(1):e1392403.

**Figures**

**Figure 1**

ROC Curve of CD44+/CD24-; DDB2, and RAD6 with therapy response. CD44+/CD24- is the blue line, RAD6 is the redline, DDB2 is the green line, and the reference line is orange.

**Figure 2**

Overview of Flow cytometry Results. (A): total cells, (B): Singlet FSC, (C): CD45 labeled pacific blue, (D): UBE2A/B labeled PE-A, (E): CD44 labeled PerCP, (F): UBE2A/B labeled PE-A(G): graphic DDB2 cell count labeled FITC-A, (H): graph of UBE2A/B cell count labeled PE-A
Figure 3

Details of Flow cytometry Cell Calculation Results. CD44+/CD24- was calculated based on the proportion of purple CD44+/CD24- cells. RAD6 (UBE2) was calculated based on the ratio of orange, purple, and single UBE2 cells; DDB2 was calculated based on the proportion of green, orange, and white colors.